The heartburn drug Prilosec got a damaging blow when a study in Circulation Research showed that the class of drugs called proton pump inhibitors (PPI), the class of drugs which includes Prilosec may lead to blood circulation problems. Prilosec…
The Oncobiologics initial public offering suffered a devastating first day. Shares ended down 20%.
Parnell Pharmaceuticals Holdings saw its shares drop by over 10% early Thursday following the pricing of its secondary offering.
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7…
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Anacor Pharmaceuticals reported its first-quarter financial results before the markets opened on Tuesday.
A Merrill Lynch report has a whole wave of companies featured as Global Ageing Primer Picks, including these biotech and pharmaceutical picks.
Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share in an initial public offering valued up to more than $79 million.
Theravance Biopharma has announced that the FDA approved its supplemental New Drug Application for Vibativ (telavancin) to expand the product's label.
Horizon Pharma reported better-than-expected first-quarter financial results before the markets opened on Monday.
A research report from Janney's Roy Buchanan issued on Friday included a fair value estimate for Geron shares that was more than 100% above the share price of the time.
When Endo International reported its first-quarter financial results on Thursday, earnings vastly underwhelmed, and analysts definitely had something to say about it.
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
